Search

everythinglearnresearchcommunity

for

Search:↓

ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.

A 19-year-old male is experiencing positive hair regrowth results after four months of using finasteride, minoxidil, and biotin. Others express admiration and share their own experiences with hair loss treatments.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

The user is using oral minoxidil and finasteride for hair loss and plans to add topical minoxidil and a dermaroller. They also use ketoconazole shampoo to support hair regrowth.

The user experienced significant hair improvement after 4 months of using 1.25mg finasteride daily and 5% Minoxidil foam. They reported no side effects and no noticeable shedding phase.

The user has been using Minoxidil for 4 years and recently added a derma pen and Trinov to their regimen, but results are inconclusive after 3 months. Some users suggest Trinov is ineffective and recommend alternatives like Clascoterone (Breezula) for better results.

The user reported noticeable hair improvement over four months using 1 mg of finasteride and weekly microneedling. Progress photos from October 2024 to January 2025 show positive changes.

Topilutamide is a potential hair loss treatment between Clascoterone and RU58841. Users discuss finding Topilutamide powder and its possible benefits for those who can't afford or tolerate other treatments.

The use of tropoelastin injections and verteporfin for hair transplant recipients to help regrow donor area hairs, as well as research done on tropoelastin injections restoring elastin in scarred heart tissue and skin. There are discussions about why it is taking so long to get cosmetic mass produced tropoelastin injectables on the market.

The conversation discusses a user's 4-month progress using topical minoxidil and 1.5-month use of topical finasteride, along with almost weekly microneedling, for hair loss. Some responses indicate noticeable improvement and encourage continued use, while others suggest it's too early to judge effectiveness and mention the possibility of a hair transplant.

The conversation is about someone's progress with hair loss treatment using Finasteride and 5% Minoxidil with Tretinoin, showing improvement in just 4 months and expecting full hair recovery by the end of the year.

A user has been using oral minoxidil for 4 months and oral finasteride for over a year without side effects. Responses praise the user's hair regrowth and healthy appearance.

A user experienced decreased free testosterone levels after three months of using finasteride, despite positive results in hair shedding reduction. They are considering switching to topical finasteride and plan to conduct further blood tests, including checking SHBG levels, to understand the hormonal changes.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

The user is experiencing potential hair regrowth after 4 months of using a minoxidil and finasteride topical spray combined with microneedling 1-2 times a week. They notice some scalp redness and irritation but are unsure if the increased hair density is due to regrowth or longer hair.

The conversation is about whether testing for free DHT is necessary before starting Finasteride for hair loss, despite having other hormone tests available. One person suggests that genetic response to DHT is more important than DHT levels and advises starting Finasteride without the free DHT test.

A dermatologist checked for hereditary hair loss using blood tests and plans to perform a trichogram. The user had slightly low Vitamin D3 levels, and the trichogram may help confirm androgenetic alopecia.

The conversation is about hair regrowth progress after 4 weeks of using 1mg Finasteride, with the user experiencing initial shedding followed by the appearance of small dark hairs on the scalp. Specific treatment mentioned is 1mg Finasteride.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

The conversation is about a hair loss treatment regimen that does not include finasteride. Specific treatments used are not mentioned.

A user created a web app called TrichoMetrics to track hair loss using photos and metrics like density and thinning. The app supports tracking treatments like Minoxidil and finasteride, with features for setting baselines, comparing progress, and logging treatment adherence.

A person shared their 4-year struggle with hair loss, including a hair transplant, side effects from hair loss medications, and other health issues. They are considering using topical Finasteride with Minoxidil and seeking advice on whether it's a good idea.

User shared progress pictures 4 months after a hair transplant in Turkey, detailing the use of dermarolling, vitamins, and starting finasteride while avoiding minoxidil. They are happy with the results so far and hope for further improvement.

The conversation is a humorous take on someone's reaction after their first dose of finasteride for hair loss. Specific treatments mentioned include scalp massage and a protocol of manifestation twice daily.

The user has tried various treatments for hair loss, including finasteride, dutasteride, and oral minoxidil, but is considering a hair transplant due to insufficient progress. Some users suggest that the treatments have at least stabilized hair loss, and recommend consulting clinics for a potential hair transplant while continuing medication.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

A 24-year-old male is considering the "Big 4" treatments (Finasteride, Minoxidil, Ketoconazole shampoo, and Microneedling) or a hair transplant for hair loss. Most users recommend starting with Finasteride and Minoxidil to stabilize hair loss before considering a transplant.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

A 23-year-old male shared his 4-month progress using a topical spray with 0.3% Finasteride, 7% Minoxidil, 2.2% Ketoconazole, and 0.2% Biotin, along with microneedling. He noticed new hair growth on his temples and experienced initial shedding, with no significant side effects after the first month.